Amiodarone-Induced Pulmonary Toxicity With Severe Pulmonary Fibrosis Complicated by Stenotrophomonas maltophilia Pneumonia: A Fatal Case Report and Literature Review
Abstract
Amiodarone is a widely used antiarrhythmic agent, valued for its efficacy and low proarrhythmic risk, but it carries a known potential for serious toxicities, particularly pulmonary toxicity. Amiodarone-induced pulmonary toxicity (APT) remains a life-threatening adverse effect. We report the case of a 75-year-old male with a 30-year history of amiodarone use (200 mg twice daily) who developed progressive respiratory distress consistent with APT. Despite treatment with broad-spectrum antibiotics and corticosteroids, his condition deteriorated. Imaging and clinical findings raised suspicion for APT, which was managed with amiodarone discontinuation and pulse-dose steroid therapy. Subsequently, he developed hospital-acquired Stenotrophomonas maltophilia pneumonia, a multidrug-resistant opportunistic infection. Targeted antibiotics were initiated based on sensitivities, but the patient progressed to respiratory failure and multiorgan dysfunction, ultimately resulting in death. This case highlights the diagnostic and therapeutic challenges of managing APT, particularly in elderly patients on long-term therapy. The absence of standardized pulmonary surveillance and delayed recognition can result in advanced disease at presentation. Superimposed nosocomial infections, especially with resistant organisms such as S. maltophilia, further complicate outcomes. Clinicians must maintain a high index of suspicion for APT in patients presenting with unexplained respiratory symptoms while on…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.